Cellectar Biosciences

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative drugs for the treatment of cancer. With a focus on targeted delivery, they strive to provide new and improved treatments that enhance the quality of life for patients. Their platform technology has the potential to deliver a wide variety of molecules directly to cancer cells, resulting in greater efficacy and fewer side effects.

Their lead program, iopofosine, is currently being evaluated in a pivotal study for Waldenstrom’s macroglobulinemia, with multiple other clinical studies underway for various B-cell malignancies and pediatric solid tumors. In their pursuit of groundbreaking treatments, Cellectar fosters a culture of innovation, collaboration, and determination throughout the company. Guided by a highly experienced executive team and board of directors, they strategically engage in partnerships and alliances to drive drug discovery and development, ensuring a broad pipeline of product candidates for areas of high unmet medical need